Diseases of the Prostate

  • Gerald W. Chodak

Abstract

Benign prostatic hypertrophy (BPH) is a common enlargement of the prostate gland that affects a high percentage of aging men. Its cause is not known, although there may be some association with high-fat diets. As a result of this enlargement patients frequently develop obstructive voiding symptoms, termed prostatism, which include decreased urinary flow rate, hesitancy, nocturia, and dribbling. Longstanding BPH may lead to acute or chronic urinary retention, bladder stone formation, hydroureteronephrosis, urinary tract infections, or renal failure. Urinary frequency or incontinence also may be associated with BPH; this often occurs when patients have chronic urinary retention.

Keywords

Prostate Cancer Radical Prostatectomy Acute Urinary Retention Urethral Stricture Luteinizing Hormone Release Hormone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Siroky MB, Olsson CA, Krane RJ. The flow rate nomogram, II: clinical correlation. J Urol 1980; 123: 208–210.PubMedGoogle Scholar
  2. 2.
    Bauer DL, Garrison R, McRoberts W. The health and cost implications of routine excretory urography before transurethral prostatectomy. J Urol 1980; 123: 386–389.PubMedGoogle Scholar
  3. 3.
    Pollack HM, Banner MP: Current status of excretory urography. Urol Clin North Am 1985; 12: 585–601.PubMedGoogle Scholar
  4. 4.
    Christoffersen I, Moller I. Eur Urol 1980; 7: 65–67.Google Scholar
  5. 5.
    Barry MJ, Mulley AG, Fowler FJ, et al. Watchful waiting vs. immediate transurethral resection for symptomatic prostatism. JAMA 1988; 259: 3010–3017.PubMedCrossRefGoogle Scholar
  6. 6.
    Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prprostatic obstruction. Br J. Urol 1978; 50: 55 1554.Google Scholar
  7. 7.
    Hedlund H, Andersson KE, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol 1983; 130: 275–278.PubMedGoogle Scholar
  8. 8.
    Peters C, Walsh P. The effect of nafareline acetate: a luteinizing hormone releasing hormone agonist on benign prostatic hyperplasia. N Engl J Med 1987; 317: 559–604.CrossRefGoogle Scholar
  9. 9.
    Klein LA, Leeming BL: Balloon dilatation for prostatic obstruction; long term follow-up. J Urol 1988; 139: 273A.Google Scholar
  10. 10.
    American Cancer Society. Cancer Facts and Figures, 1988. New York, NY American Cancer Society; 1988.Google Scholar
  11. 11.
    Brooman PJC, Griffiths, GJ, Roberts E, et al. Perirectal ultrasound in the investigation of prostatic disease. Clin Radiol 1981; 32: 669–676.PubMedCrossRefGoogle Scholar
  12. 12.
    Chodak GW, Wald V, Parmer E, et al. Comparison of digital examination and transrectal ultrasonography for the diagnosis of prostatic cancer. J Urol 1986; 135: 95 1954.Google Scholar
  13. 13.
    Cooner WH, Eggers GW, Lichtenstein P. New hope for early diagnosis. Ala Med 187; 56: 13–16.Google Scholar
  14. 14.
    Lee F, Littrup PJ, Torp-Pedersen ST, et al. Prostate cancer: comparison of transrectal US and digital rectal examination for screening. Radiology 1988; 168: 389–394.PubMedGoogle Scholar
  15. 15.
    Davidson P, Malament M: Urinary contamination as a result of transrectal biopsy of the prostate. J Urol 1971; 105: 545–546.Google Scholar
  16. 16.
    Fawcett DP, Eykyn S, Bultitude MI. Urinary tract infection following trans-rectal biopsy of the prostate. Br J Urol 1975; 47: 679–681.PubMedCrossRefGoogle Scholar
  17. 17.
    Wendel RG, Evans AT. Complications of punch biopsy of the prostate gland. J Urol 1967; 97: 122–126.PubMedGoogle Scholar
  18. 18.
    Kline TS, Kelsey DM, Kohler FP. Prostatic carcinoma and needle aspiration biopsy. Am J Pasthol 1977; 67: 131–133.Google Scholar
  19. 19.
    Zincke H, Campbell JT, Utz DC, et al. Confidence in the negative transrectal needle biopsy. Surg Gynecol Obstet 1973; 136: 78–80.PubMedGoogle Scholar
  20. 20.
    Chodak GW, Steinberg GD, Bibbo M, et al. The role of transrectal aspiration biopsy in the diagnosis of prostatic cancer. J Urol 1986; 135: 299–302.PubMedGoogle Scholar
  21. 21.
    Esposi PL, Elman A, Norlen H. Complications of transrectal aspiration biopsy of the prostate. Scand J Urol Nephrol 1975; 9: 208–213.CrossRefGoogle Scholar
  22. 22.
    Rifkin MD, Kurtz AB, Goldberg BG. Sonographically guided transperineal prostatic biopsy: preliminary experience with a longitudinal linear-array transducer. Am J Radiol1983; 140: 745–747.Google Scholar
  23. 23.
    Stamey T, Yang N, Hay AR, et al. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317; 909–916.PubMedCrossRefGoogle Scholar
  24. 24.
    Catalona WJ, Stein AJ. Staging errors in clinically localized prostate cancer. J Urol 1982; 127: 452–456.PubMedGoogle Scholar
  25. 25.
    Stamey TA. Cancer of the prostate. Monogr Urol 1983;4:68–92. Google Scholar
  26. 26.
    Pontes JE, Eisenkraft S, Watanabe H, et al. Preoperative evaluation of localized prostatic carcinoma by trans-rectal ultrasonography. J Urol 1985; 134: 289–291.PubMedGoogle Scholar
  27. 27.
    Salo JO, Kivisaari L, Rannikko S, et al. Computerized tomography and transrectal ultrasound in the assessment of local extension of prostatic cancer before radical retropubic prostatectomy. J Urol 1987; 137: 435–438.PubMedGoogle Scholar
  28. 28.
    Consensus Conference. The management of clinically localized prostate cancer. JAMA 1987; 258: 2727–2730.CrossRefGoogle Scholar
  29. 29.
    McNeal JE, Kindrachuk RA, Freiha FS, et al. Patterns of progression in prostate cancer. Lancet 1986; 1: 60–62.PubMedCrossRefGoogle Scholar
  30. 30.
    Lange PH, Reddy PK, Medini E, et al. Radiation therapy as adjunctive treatment after radical prostatectomy. NCI Monogr 1988; 7: 141–150.PubMedGoogle Scholar
  31. 31.
    Veterans Administration Cooperative Urological Research Group. Estrogen treatment for cancer of the prostate: early results with three doses of diethylstilbestrol and placebo. Cancer 1970; 26: 257–261.CrossRefGoogle Scholar
  32. 32.
    Huggins, C, Hodges CV: Studies on prostatic cancer, I: the effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297.Google Scholar
  33. 33.
    Benson MC, Coffey DS. Prostate cancer research: current concepts and controversies. Semin Urol 1983; 1: 323–330.PubMedGoogle Scholar
  34. 34.
    Resnick MI. Hormonal therapy in prostatic carcinoma. Urology 1984; 24: 18–23.PubMedCrossRefGoogle Scholar
  35. 35.
    Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. N Engl J Med 1984; 311: 1281–1286.CrossRefGoogle Scholar
  36. 36.
    Byar DP. The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostrate. Cancer 1972; 32: 1126–1130.CrossRefGoogle Scholar
  37. 37.
    Schally AV, Kastin AJ, Coy DH. LH-releasing hormone and its analogues: recent basic and clinical investigations. Int J Fertil 1976; 21: 1–30.PubMedGoogle Scholar
  38. 38.
    Eisenberg MA. Chemotherapy for prostate cancer. NCI Monogr 1988; 7: 151–163.Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Gerald W. Chodak

There are no affiliations available

Personalised recommendations